Pharma Mar SA
Belén Sopesén has a diverse work experience spanning multiple companies and roles. Belén started their career at CIBEST, where they worked as a Clinical Research Associate and later became the Head of the Training and Quality Assurance Unit. Belén then co-founded Qualysite Consultores, where they served as an Entrepreneur and Technical Director.
In 2005, Belén joined NOSCIRA S.A., part of the PharmaMar Group, where they held various positions including Managing Director and Director of Quality Assurance. During their time at NOSCIRA, they were involved in the research and development of innovative treatments for neurodegenerative diseases.
In 2014, they became a Member of the Board at XYLAZEL S.A., representing the PharmaMar Group in the Consumer Chemicals sector. Belén also served as the General Manager at Xylazel S.A., another PharmaMar Group company. Here, they played a key role in the sale of the company to AkzoNobel and implemented a global Strategic Plan.
In 2019, Belén joined Sylentis as a Member of the Board, representing the PharmaMar Group. Lastly, they are currently working at PhamaMar as the Director of Corporate Affairs, where they have taken on multiple responsibilities including the selection and start-up of the Virology unit, conducting clinical operations, and leading Phase III studies for combating COVID-19.
Belén Sopesén obtained a Licenciatura degree in Farmacia from CEU San Pablo y Universidad Complutense de Madrid in 1993. Belén also completed a Doctor of Pharmacy (Pharm.D.) degree from Universidad Complutense de Madrid between 1994 and 1998. In 2006, they attended IESE Business School for the Management Development Programme (PDD). Additionally, in 1993, they participated in the Programa Comett at Fundación Universidad Empresa, focusing on experimental research.
This person is not in the org chart
This person is not in any offices
Pharma Mar SA
Pharma Mar SA is a Spain-based company engaged in the bio therapeutic drugs manufacture. The Company focuses on research, development and marketing of bio-active principles, primarily from marine origin, for application in human diseases treatment, including antitumour, antiviral and immunomodulation, as well as tropical diseases areas. It manufactures and sells Yondelis, a synthetically modified antitumor agent, which is derived from sea squirts and is implemented in the treatment of soft tissue sarcomas and relapsed ovarian cancer. Furthermore, the Company's products pipeline comprises drug candidates and agents for cancer treatment, such as Aplidin, PM01183 and PM060184. The Company operates through subsidiaries in Italy, Germany, France, and the United States, among others.